Urologie pro praxi 2/2026
Individualization of systemic treatment for advanced prostate cancer
Renal cell carcinoma (RCC) accounts for approximately 2–3 % of all malignancies, and its incidence has been steadily increasing. From the perspective of systemic therapy, immunotherapy has become a key pillar of modern RCC treatment. Over the past decade, immune checkpoint inhibitors (ICI) have emerged as an essential component of therapy for both advanced disease and localized disease at high risk of relapse. This article summarizes the role of immunotherapy in the management of metastatic RCC and its position in the adjuvant setting following surgical treatment.
Keywords: renal cell carcinoma, imunotherapy, adjuvant treatment.
